Overview

Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC

Status:
Active, not recruiting

Trial end date:
2027-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety and efficacy of MILs™ - NSCLC alone and in combination with nivolumab with or without tadalafil in subjects with locally advanced and unresectable or metastatic NSCLC who are refractory or relapsing to a PD-1 containing regimen.

Phase:

Phase 2

Details

Lead Sponsor:

WindMIL Therapeutics

Collaborator:

Bristol-Myers Squibb

Treatments:

Nivolumab
Tadalafil